# Entasis Therapeutics Holdings

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/entasis-therapeutics-holdings

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.entasistx.com
- Total disclosed funding: $82M
- Latest round: Series B (Sep 5, 2017)
- Investors on record: 7

## About

Entasis Therapeutics Holdings Inc. is a biopharmaceutical company focused on developing innovative therapies to combat drug-resistant infections, particularly targeting Gram-negative bacteria.Founded in 2015 and headquartered in Waltham, US, Entasis Therapeutics specializes in developing treatments for serious infections. The company has not undergone any significant pivots or changes in its business strategy. Manos Perros serves as both the CEO and the founder, bringing prior experience in the pharmaceutical industry. The company has raised a total of USD 15.00 mn through a series of funding rounds, with its latest round being a Private Placement/Follow on amounting to USD 15.00 mn from Innoviva, Inc.Entasis Therapeutics is dedicated to addressing critical care and infectious diseases through its innovative product offerings. Key products include the antibiotic therapies designed for treating complicated infections caused by drug-resistant bacteria, with a focus on healthcare providers managing serious medical conditions. Their products are marketed primarily in North America and Europe, catering to hospitals and healthcare institutions.In its most recent financial year, Entasis Therapeutics reported zero revenue. As of 2021, the company recorded an EBITDA of USD -52.21 mn, reflecting its ongoing investments in product development and clinical trials.Entasis Therapeutics plans to utilize its recent funding to advance the clinical and preclinical development of its product pipeline, specifically targeting drug-resistant Gram-negative infections. The company is also looking to expand into additional markets within Europe and Asia by 2023, aiming to enhance access to its therapies. Recent funding rounds will support these initiatives, allowing the company to solidify its position in the biopharmaceutical industry.

## Funding rounds

- Series B, Sep 5, 2017, $32M — Sofinnova Investments, TPG Biotech, Pivotal Life Sciences
- Series B, Apr 4, 2016, $50M — Frazier Healthcare Partners, Novo Holdings, Clarus Ventures, Eventide Asset Management

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B
- Novo Holdings — Series B
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series B
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series B
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series B